| 國立臺灣大學 |
2014 |
Calreticulin mutation was rarely detected in patients with myelodysplastic syndrome
|
Hou, H-A; Kuo, Y-Y; Chou, W-C; Chen, P-H; Tien, H-F; 田蕙芬; 郭遠燁; 周文堅; 侯信安 |
| 臺大學術典藏 |
2014 |
Health risk assessment for residents exposed to atmospheric diesel exhaust particles in southern region of Taiwan
|
Chio, C.-P. ; Liao, C.-M. ; Tsai, Y.-I. ; Cheng, M.-T. ; Chou, W.-C.; CHIA-PIN CHIO |
| 臺大學術典藏 |
2014 |
Clinical implications of the SETBP1 mutation in patients with primary myelodysplastic syndrome and its stability during disease progression
|
HWEI-FANG TIEN; Chen Y.-C.; Wu S.-J.; Tsay W.; Huang S.-Y.; Ko B.-S.; Liu C.-W.; Liu M.-C.; Lee F.-Y.; Chiang Y.-C.; Huang C.-F.; Hou H.-A.; Kuo Y.-Y.; Tang J.-L.; Chou W.-C.; Yao M.; Lai Y.-J.; Lin C.-C.; Chen C.-Y.; Liu C.-Y.; Tseng M.-H. |
| 臺大學術典藏 |
2014 |
Gfi-1 is the transcriptional repressor of SOCS1 in acute myeloid leukemia cells
|
Lee M.-C.; Kuo Y.-Y.; Chou W.-C.; Hou H.-A.; Hsiao M.; HWEI-FANG TIEN |
| 臺大學術典藏 |
2014 |
Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma
|
HWEI-FANG TIEN; Chou S.-J.; Chou W.-C.; Tsay W.; Chen C.-Y.; Hou H.-A.; Lu H.-Y.; Chen Y.-C.; Wu S.-J.; Tang J.-L.; Lin H.-H.; Yao M.; Huang S.-Y.; Lin C.-W. |
| 臺大學術典藏 |
2014 |
The N-terminal CEBPA mutant in acute myeloid leukemia impairs CXCR4 expression
|
Lee F.-Y.; Tseng M.-H.; Huang C.-F.; Chen P.-H.; Li L.-Y.; Chen Y.-K.; Hou H.-A.; Kuo Y.-Y.; HWEI-FANG TIEN; Liu M.-C.; Liu C.-W.; Chou W.-C.; Liu C.-Y.; Tang J.-L.; Yao M. |
| 臺大學術典藏 |
2014 |
SF3B1 mutations in patients with myelodysplastic syndromes: The mutation is stable during disease evolution
|
Tseng M.-H.; Chen C.-Y.; Liu C.-Y.; Kuo Y.-Y.; Wu S.-J.; Chou W.-C.; Hou H.-A.; Lin C.-C.; Huang C.-F.; Lee F.-Y.; Liu M.-C.; Liu C.-W.; Tang J.-L.; Yao M.; Huang S.-Y.; Hsu S.-C.; Ko B.-S.; Tsay W.; Chen Y.-C.; HWEI-FANG TIEN |
| 臺大學術典藏 |
2014 |
Integration of cytogenetic and molecular alterations in risk stratification of 318 patients with de novo non-M3 acute myeloid leukemia
|
Lee M.-C.; Liu M.-C.; Kuo Y.-Y.; Lee F.-Y.; Huang C.-F.; Chiang Y.-C.; Tseng M.-H.; Lai Y.-J.; Tang J.-L.; Chen C.-Y.; Liu C.-Y.; Chou W.-C.; Lin C.-C.; Hou H.-A.; Liu C.-W.; Lin L.-I.; Yao M.; Huang S.-Y.; Ko B.-S.; Hsu S.-C.; Wu S.-J.; Tsay W.; Chen Y.-C.; HWEI-FANG TIEN |
| 臺大學術典藏 |
2014 |
Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma
|
MING YAO; Lin C.-W.; Lin H.-H.; Huang S.-Y.; Chou S.-J.; Chou W.-C.; Tsay W.; Chen C.-Y.; Hou H.-A.; Chen Y.-C.; Lu H.-Y.; Wu S.-J.; Tang J.-L.; Tien H.-F. |
| 臺大學術典藏 |
2014 |
The N-terminal CEBPA mutant in acute myeloid leukemia impairs CXCR4 expression
|
Tseng M.-H.; Li L.-Y.; Chen P.-H.; Chen Y.-K.; Hou H.-A.; Kuo Y.-Y.; Huang C.-F.; Lee F.-Y.; Liu M.-C.; Liu C.-W.; Chou W.-C.; Liu C.-Y.; Tang J.-L.; MING YAO; Tien H.-F. |
